NCT00653055View on ClinicalTrials.gov

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

December 31, 2001

Study Completion Date

December 31, 2001

Conditions
To Determine Bioequivalence Under Fasting Conditions
Interventions
DRUG

Cabergoline

Tablets, 0.5 mg (2 x 0.5 mg dose),fasting

DRUG

Dostinex

Tablets, 0.5 mg (2 x 0.5 mg dose), fasting

Trial Locations (1)

GiV 2K8

Anapharm, Inc., Sainte-Foy

Sponsors

Collaborators (1)

Anapharm
All Listed Sponsors
collaborator

Anapharm

INDUSTRY

lead

Par Pharmaceutical, Inc.

INDUSTRY

NCT00653055 - Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions | Biotech Hunter | Biotech Hunter